UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
A shelf registration statement relating to the ordinary shares was
previously filed with the
Goldman Sachs & Co. LLC, c/o: Prospectus Department, 200 West Street, New York, New York10282, or via telephone at 866-471-2526, or via email: email@example.com; or J.P. Morgan Securities LLC, c/o: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York11717 or via telephone at 866-803-9204, or via email: firstname.lastname@example.org; or Jefferies LLC, c/o: Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2nd Floor, New York, New York10022, or via telephone at 877-821-7388, or via email: email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Director, Corporate Communications & Investor Relations